Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer
Purpose FOLFIRINOX is the standard therapy in patients with unresectable pancreatic cancer (PC). However, FOLFIRINOX frequently induces febrile neutropenia (FN) and neutropenia. The purpose of this study was to explore risk factors for FN and grade 4 neutropenia (NP G4) in patients receiving FOLFIRI...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2020-04, Vol.85 (4), p.651-659 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 659 |
|---|---|
| container_issue | 4 |
| container_start_page | 651 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 85 |
| creator | Keum, Jiyoung Lee, Hee Seung Kang, Huapyong Jo, Jung Hyun Chung, Moon Jae Park, Jeong Youp Park, Seung Woo Song, Si Young Bang, Seungmin |
| description | Purpose
FOLFIRINOX is the standard therapy in patients with unresectable pancreatic cancer (PC). However, FOLFIRINOX frequently induces febrile neutropenia (FN) and neutropenia. The purpose of this study was to explore risk factors for FN and grade 4 neutropenia (NP G4) in patients receiving FOLFIRINOX for PC.
Methods
We collected data on 106 patients with PC treated with first-line FOLFIRINOX between 2015 and 2017 using the Pancreatic Cancer Cohort Registry of Severance Hospital in Seoul, Korea.
Results
Multivariate logistic regression analysis showed that female (OR, 3.24;
P
= 0.023), Eastern Cooperative Oncology Group performance status (OR, 3.70;
P
= 0.024), overweight (OR, 4.25;
P
= 0.022), and initial biliary stent insertion (OR, 4.22;
P
= 0.008) were significantly related to a high risk of FN. Time-dependent bias was reduced using Cox regression analysis, which revealed that female (OR, 2.29;
P
= 0.041), overweight (OR, 2.67;
P
= 0.022), and initial biliary stent insertion (OR, 2.59;
P
= 0.016) were statistically significant predictors. Regarding NP G4, female sex (OR, 2.90;
P
= 0.016) and overweight (OR, 4.07;
P
= 0.033) were identified as risk factors in multivariate analysis; however, in Cox regression analysis, tumor in the head of the pancreas (OR, 1.96;
P
= 0.027) and hemoglobin (g/dL |
| doi_str_mv | 10.1007/s00280-020-04051-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2385885277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2385885277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-bcc5e7f55ec6364b01832b141bd09d8e3e7e2439fe682093b120e368113e81943</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoWqt_wIMEPK9OMkk3PYpYLRQLfoC3kE1na7Tu1mSL-u-N1o-bhyEzyfu-Qx7GDgQcC4DyJAFIAwXIXAq0KN42WE8olAUYhZusB6hUoUtQO2w3pUcAUAJxm-2gFEYrgz2WbkIzX1Dhqeko8hjSE6-d79rIXeMW7ykkXudhNJ2Mxtfjq-k9dym1PriOZrymKoYF8YZWXWyX1ATHQ8OXrgs5L_HX0D3kqfGR8pXnPrcU99hW7RaJ9r_PPrsbnd-eXRaT6cX47HRSeCx1V1TeayprrckPcKAqEAZlJZSoZjCcGUIqSSoc1jQwEoZYCQmEAyMEkhFDhX12tM5dxvZlRamzj-0q5l8lK9FoY7Qsy6ySa5WPbUqRaruM4dnFdyvAfnK2a842c7ZfnO1bNh1-R6-qZ5r9Wn7AZgGuBSk_NXOKf7v_if0ABfCJHA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2385885277</pqid></control><display><type>article</type><title>Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer</title><source>Springer Nature - Complete Springer Journals</source><creator>Keum, Jiyoung ; Lee, Hee Seung ; Kang, Huapyong ; Jo, Jung Hyun ; Chung, Moon Jae ; Park, Jeong Youp ; Park, Seung Woo ; Song, Si Young ; Bang, Seungmin</creator><creatorcontrib>Keum, Jiyoung ; Lee, Hee Seung ; Kang, Huapyong ; Jo, Jung Hyun ; Chung, Moon Jae ; Park, Jeong Youp ; Park, Seung Woo ; Song, Si Young ; Bang, Seungmin</creatorcontrib><description>Purpose
FOLFIRINOX is the standard therapy in patients with unresectable pancreatic cancer (PC). However, FOLFIRINOX frequently induces febrile neutropenia (FN) and neutropenia. The purpose of this study was to explore risk factors for FN and grade 4 neutropenia (NP G4) in patients receiving FOLFIRINOX for PC.
Methods
We collected data on 106 patients with PC treated with first-line FOLFIRINOX between 2015 and 2017 using the Pancreatic Cancer Cohort Registry of Severance Hospital in Seoul, Korea.
Results
Multivariate logistic regression analysis showed that female (OR, 3.24;
P
= 0.023), Eastern Cooperative Oncology Group performance status (OR, 3.70;
P
= 0.024), overweight (OR, 4.25;
P
= 0.022), and initial biliary stent insertion (OR, 4.22;
P
= 0.008) were significantly related to a high risk of FN. Time-dependent bias was reduced using Cox regression analysis, which revealed that female (OR, 2.29;
P
= 0.041), overweight (OR, 2.67;
P
= 0.022), and initial biliary stent insertion (OR, 2.59;
P
= 0.016) were statistically significant predictors. Regarding NP G4, female sex (OR, 2.90;
P
= 0.016) and overweight (OR, 4.07;
P
= 0.033) were identified as risk factors in multivariate analysis; however, in Cox regression analysis, tumor in the head of the pancreas (OR, 1.96;
P
= 0.027) and hemoglobin (g/dL < 12) (OR, 1.87;
P
= 0.049) were also identified as risk factors.
Conclusion
Female sex, overweight, and initial biliary stent insertion were independent risk factors for the occurrence of FN in patients with unresectable PC treated with FOLFIRINOX.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-020-04051-x</identifier><identifier>PMID: 32185483</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Body weight ; Cancer ; Cancer Research ; Factor analysis ; Hemoglobin ; Implants ; Insertion ; Medicine ; Medicine & Public Health ; Multivariate analysis ; Neutropenia ; Oncology ; Original Article ; Overweight ; Pancreas ; Pancreatic cancer ; Pharmacology/Toxicology ; Regression analysis ; Risk analysis ; Risk factors ; Statistical analysis ; Stents ; Surgical implants ; Time dependence</subject><ispartof>Cancer chemotherapy and pharmacology, 2020-04, Vol.85 (4), p.651-659</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-bcc5e7f55ec6364b01832b141bd09d8e3e7e2439fe682093b120e368113e81943</citedby><cites>FETCH-LOGICAL-c375t-bcc5e7f55ec6364b01832b141bd09d8e3e7e2439fe682093b120e368113e81943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-020-04051-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-020-04051-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32185483$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keum, Jiyoung</creatorcontrib><creatorcontrib>Lee, Hee Seung</creatorcontrib><creatorcontrib>Kang, Huapyong</creatorcontrib><creatorcontrib>Jo, Jung Hyun</creatorcontrib><creatorcontrib>Chung, Moon Jae</creatorcontrib><creatorcontrib>Park, Jeong Youp</creatorcontrib><creatorcontrib>Park, Seung Woo</creatorcontrib><creatorcontrib>Song, Si Young</creatorcontrib><creatorcontrib>Bang, Seungmin</creatorcontrib><title>Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose
FOLFIRINOX is the standard therapy in patients with unresectable pancreatic cancer (PC). However, FOLFIRINOX frequently induces febrile neutropenia (FN) and neutropenia. The purpose of this study was to explore risk factors for FN and grade 4 neutropenia (NP G4) in patients receiving FOLFIRINOX for PC.
Methods
We collected data on 106 patients with PC treated with first-line FOLFIRINOX between 2015 and 2017 using the Pancreatic Cancer Cohort Registry of Severance Hospital in Seoul, Korea.
Results
Multivariate logistic regression analysis showed that female (OR, 3.24;
P
= 0.023), Eastern Cooperative Oncology Group performance status (OR, 3.70;
P
= 0.024), overweight (OR, 4.25;
P
= 0.022), and initial biliary stent insertion (OR, 4.22;
P
= 0.008) were significantly related to a high risk of FN. Time-dependent bias was reduced using Cox regression analysis, which revealed that female (OR, 2.29;
P
= 0.041), overweight (OR, 2.67;
P
= 0.022), and initial biliary stent insertion (OR, 2.59;
P
= 0.016) were statistically significant predictors. Regarding NP G4, female sex (OR, 2.90;
P
= 0.016) and overweight (OR, 4.07;
P
= 0.033) were identified as risk factors in multivariate analysis; however, in Cox regression analysis, tumor in the head of the pancreas (OR, 1.96;
P
= 0.027) and hemoglobin (g/dL < 12) (OR, 1.87;
P
= 0.049) were also identified as risk factors.
Conclusion
Female sex, overweight, and initial biliary stent insertion were independent risk factors for the occurrence of FN in patients with unresectable PC treated with FOLFIRINOX.</description><subject>Body weight</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Factor analysis</subject><subject>Hemoglobin</subject><subject>Implants</subject><subject>Insertion</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate analysis</subject><subject>Neutropenia</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Overweight</subject><subject>Pancreas</subject><subject>Pancreatic cancer</subject><subject>Pharmacology/Toxicology</subject><subject>Regression analysis</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Statistical analysis</subject><subject>Stents</subject><subject>Surgical implants</subject><subject>Time dependence</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kE1LAzEQhoMoWqt_wIMEPK9OMkk3PYpYLRQLfoC3kE1na7Tu1mSL-u-N1o-bhyEzyfu-Qx7GDgQcC4DyJAFIAwXIXAq0KN42WE8olAUYhZusB6hUoUtQO2w3pUcAUAJxm-2gFEYrgz2WbkIzX1Dhqeko8hjSE6-d79rIXeMW7ykkXudhNJ2Mxtfjq-k9dym1PriOZrymKoYF8YZWXWyX1ATHQ8OXrgs5L_HX0D3kqfGR8pXnPrcU99hW7RaJ9r_PPrsbnd-eXRaT6cX47HRSeCx1V1TeayprrckPcKAqEAZlJZSoZjCcGUIqSSoc1jQwEoZYCQmEAyMEkhFDhX12tM5dxvZlRamzj-0q5l8lK9FoY7Qsy6ySa5WPbUqRaruM4dnFdyvAfnK2a842c7ZfnO1bNh1-R6-qZ5r9Wn7AZgGuBSk_NXOKf7v_if0ABfCJHA</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Keum, Jiyoung</creator><creator>Lee, Hee Seung</creator><creator>Kang, Huapyong</creator><creator>Jo, Jung Hyun</creator><creator>Chung, Moon Jae</creator><creator>Park, Jeong Youp</creator><creator>Park, Seung Woo</creator><creator>Song, Si Young</creator><creator>Bang, Seungmin</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20200401</creationdate><title>Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer</title><author>Keum, Jiyoung ; Lee, Hee Seung ; Kang, Huapyong ; Jo, Jung Hyun ; Chung, Moon Jae ; Park, Jeong Youp ; Park, Seung Woo ; Song, Si Young ; Bang, Seungmin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-bcc5e7f55ec6364b01832b141bd09d8e3e7e2439fe682093b120e368113e81943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Body weight</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Factor analysis</topic><topic>Hemoglobin</topic><topic>Implants</topic><topic>Insertion</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate analysis</topic><topic>Neutropenia</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Overweight</topic><topic>Pancreas</topic><topic>Pancreatic cancer</topic><topic>Pharmacology/Toxicology</topic><topic>Regression analysis</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Statistical analysis</topic><topic>Stents</topic><topic>Surgical implants</topic><topic>Time dependence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Keum, Jiyoung</creatorcontrib><creatorcontrib>Lee, Hee Seung</creatorcontrib><creatorcontrib>Kang, Huapyong</creatorcontrib><creatorcontrib>Jo, Jung Hyun</creatorcontrib><creatorcontrib>Chung, Moon Jae</creatorcontrib><creatorcontrib>Park, Jeong Youp</creatorcontrib><creatorcontrib>Park, Seung Woo</creatorcontrib><creatorcontrib>Song, Si Young</creatorcontrib><creatorcontrib>Bang, Seungmin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keum, Jiyoung</au><au>Lee, Hee Seung</au><au>Kang, Huapyong</au><au>Jo, Jung Hyun</au><au>Chung, Moon Jae</au><au>Park, Jeong Youp</au><au>Park, Seung Woo</au><au>Song, Si Young</au><au>Bang, Seungmin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>85</volume><issue>4</issue><spage>651</spage><epage>659</epage><pages>651-659</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>Purpose
FOLFIRINOX is the standard therapy in patients with unresectable pancreatic cancer (PC). However, FOLFIRINOX frequently induces febrile neutropenia (FN) and neutropenia. The purpose of this study was to explore risk factors for FN and grade 4 neutropenia (NP G4) in patients receiving FOLFIRINOX for PC.
Methods
We collected data on 106 patients with PC treated with first-line FOLFIRINOX between 2015 and 2017 using the Pancreatic Cancer Cohort Registry of Severance Hospital in Seoul, Korea.
Results
Multivariate logistic regression analysis showed that female (OR, 3.24;
P
= 0.023), Eastern Cooperative Oncology Group performance status (OR, 3.70;
P
= 0.024), overweight (OR, 4.25;
P
= 0.022), and initial biliary stent insertion (OR, 4.22;
P
= 0.008) were significantly related to a high risk of FN. Time-dependent bias was reduced using Cox regression analysis, which revealed that female (OR, 2.29;
P
= 0.041), overweight (OR, 2.67;
P
= 0.022), and initial biliary stent insertion (OR, 2.59;
P
= 0.016) were statistically significant predictors. Regarding NP G4, female sex (OR, 2.90;
P
= 0.016) and overweight (OR, 4.07;
P
= 0.033) were identified as risk factors in multivariate analysis; however, in Cox regression analysis, tumor in the head of the pancreas (OR, 1.96;
P
= 0.027) and hemoglobin (g/dL < 12) (OR, 1.87;
P
= 0.049) were also identified as risk factors.
Conclusion
Female sex, overweight, and initial biliary stent insertion were independent risk factors for the occurrence of FN in patients with unresectable PC treated with FOLFIRINOX.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32185483</pmid><doi>10.1007/s00280-020-04051-x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2020-04, Vol.85 (4), p.651-659 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_2385885277 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Body weight Cancer Cancer Research Factor analysis Hemoglobin Implants Insertion Medicine Medicine & Public Health Multivariate analysis Neutropenia Oncology Original Article Overweight Pancreas Pancreatic cancer Pharmacology/Toxicology Regression analysis Risk analysis Risk factors Statistical analysis Stents Surgical implants Time dependence |
| title | Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T11%3A31%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Single-center%20risk%20factor%20analysis%20for%20FOLFIRINOX%20associated%20febrile%20neutropenia%20in%20patients%20with%20pancreatic%20cancer&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Keum,%20Jiyoung&rft.date=2020-04-01&rft.volume=85&rft.issue=4&rft.spage=651&rft.epage=659&rft.pages=651-659&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/s00280-020-04051-x&rft_dat=%3Cproquest_cross%3E2385885277%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2385885277&rft_id=info:pmid/32185483&rfr_iscdi=true |